Forward PE Ratio: 36.64
The forward PE ratio is 36.64 as of Thursday, July 9, 2026.
Forward PE Ratio (36.64) = Close Price ($72.19) / Consensus Forward EPS ($1.92)
TMDX Forward PE Ratio Metrics
FORWARD PE RATIO
36.64
TMDX Competitors' Forward PE Ratio
TransMedics Group, Inc.
Market Cap
$2.49B
Forward PE Ratio
36.64
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| TransMedics Group, Inc. (TMDX) | $2.49B | 36.64 |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.38B | 8.31 |
| Teladoc Health, Inc. (TDOC)vs › | $1.66B | N/A |
| National Research Corporation (NRC)vs › | $489.27M | 24.85 |
| Shoulder Innovations, Inc. (SI)vs › | $440.27M | N/A |
| 23andMe Holding Co. (ME)vs › | $15.31M | N/A |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.91B | N/A |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $8.04B | 31.40 |
| Oscar Health, Inc. (OSCR)vs › | $8.09B | 29.55 |
| Henry Schein, Inc. (HSIC)vs › | $9.55B | 15.56 |
Trailing vs Forward
Trailing P/E
16.1
reported TTM EPS
Forward P/E
36.6
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $1.92 implies -56.1% EPS decline vs the reported trailing $4.37.
Forward P/E by Fiscal Year
View All Analyst EstimatesAt today's $72.19 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $1.92 | $1.54 – $2.15 | 6 | 37.5x |
| 2027-12-31 | $3.28 | $2.19 – $4.40 | 7 | 22.0x |
| 2028-12-31 | $4.54 | $3.12 – $5.90 | 5 | 15.9x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
Forward PE Ratio Formula & Definition
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Forward PE Ratio FAQ
- What is the forward PE ratio for TransMedics Group, Inc. (TMDX)?
- The forward PE ratio for TMDX stock is 36.64.
Related Metrics
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein